SCHEMBL6488296

SCHEMBL6488296

Cc1ccc2[nH]c3c(c2c1)/C(=N/NC(=N)N)CCC3

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.43
F2 P00734 1/20 0.41
MAPT P10636 5/20 0.41
ALDH1A1 P00352 3/20 0.41
GAA P10253 2/20 0.41
HTT P42858 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 4/20 0.40
KDM4E B2RXH2 2/20 0.40
ALOX12 P18054 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
KCNA5 P22460 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
BAZ2B Q9UIF8 1/20 0.37
SIRT1 Q96EB6 3/20 0.37
RECQL P46063 1/20 0.37
SIRT2 Q8IXJ6 1/20 0.37
KCNH2 Q12809 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488300 1.00 PTGES (0.43) PTGESF2MAPTALDH1A1GAA
SCHEMBL6488195 0.86 MAP3K14 (0.46) F2MAPTALDH1A1GAAMEN1
SCHEMBL6488914 0.86 F2 (0.41) F2MAPTALDH1A1MEN1KMT2A
SCHEMBL6495460 0.86 MAPT (0.51) F2MAPTALDH1A1GAAHTT
SCHEMBL6488907 0.86 F2 (0.41) F2MAPTALDH1A1MEN1KMT2A
SCHEMBL6495462 0.86 MAPT (0.51) F2MAPTALDH1A1GAAHTT
SCHEMBL6488194 0.86 MAP3K14 (0.46) F2MAPTALDH1A1GAAMEN1
SCHEMBL6502689 0.83 KDM4E (0.43) F2MAPTALDH1A1GAAMEN1
SCHEMBL6502691 0.83 KDM4E (0.43) F2MAPTALDH1A1GAAMEN1
SCHEMBL6488069 0.82 ALDH1A1 (0.35) PTGESF2MAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951881-B2 (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-10-04 US disclosed
US-20030232843-A1 (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232843-A1 (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR1A PTGES 933/4885F2 4458/4885MAPT 1293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.